Expected Impact:contribute to IHI JU SRIA objectives, driving cross-sectoral health innovation for a competitive European health industry. Contribute to the objectives of the Industrial Strategy for Europe and Pharmaceutical Strategy for Europe; understanding human health and environmental risks from PFAS in healthcare from a life cycle perspective, i.e. mapping where PFAS is introduced in the healthcare industry and removal, where possible; manage PFAS risks with novel mitigation measures, including safe disposal, reuse, and recycling; develop methodologies and solutions for PFAS replacement that meet regulatory requirements without compromising efficacy, quality, safety, or environmental performance; position the EU as a leader in safe, sustainable PFAS alternatives through industry-academia collaboration; foster medicine supply in the EU, avoid non-EU dependencies, and keep R&D activities in Europe for ...
This IHI JU topic will enable and directly contribute to the EU health priorities, initiatives, and policies. Healthcare products containing PFAS are often essential for the health of citizens in Europe and worldwide. The proposed IHI JU topic would strengthen collaboration between healthcare system stakeholders to reduce emissions of, and exposure to PFAS, evaluate alternatives and therefore, contribute to the EU Chemicals Strategy for Sustainability of the EU Green Deal.
The action under this topic is expected to achieve the following impacts:
